エグザクトサイエンス株式会社（本社：東京都千代田区、代表取締役：ジェフリー・ヘイゼマー）は、2021年12月1日に開催されました中央社会保険医療協議会にて、「オンコタイプDX乳がん再発スコア®プログラム」（一般的名称：腫瘍悪性度判定支援 ...

エグザクトサイエンスは7月6日、「オンコタイプ DX 乳がん再発スコアプログラム」が9月1日より保険適用となる見込みだと発表した。中央社会保険医療協議会（中医協）が保険適用を7月5日付けで了承した。 「オンコタイプ DX 乳がん再発スコアプログラム ...

An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification in hormone receptor (HR)-positive, ...

The new risk score could help better manage the follow-up care for patients who've had pancreatic tumors surgically removed, and whose cancers have not spread to their lymph nodes, researchers wrote ...

Add Yahoo as a preferred source to see more of our stories on Google. The new risk score could help better manage the follow-up care for patients who've had pancreatic tumors surgically removed, and ...

The score could help better manage the follow-up care for patients who’ve had pancreatic tumors surgically removed, and whose cancers have not spread to their lymph nodes, researchers wrote Dec. 17 in ...